Featuring an interview with Dr Marwan Fakih, including the following topics:
- Etiology and incidence of squamous cell carcinoma of the anal canal (SCAC) (0:00)
- Novel therapeutic strategies for the treatment of SCAC: Immunotherapy combinations and monitoring for recurrence with circulating tumor DNA assessment (4:37)
- Perspectives on the overall survival benefit observed with first-line retifanlimab and carboplatin/paclitaxel; potential for cure for patients with SCAC (8:22)
- Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives retifanlimab with carboplatin/paclitaxel (16:56)
- Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives single-agent immunotherapy (25:22)
- Case: A woman in her 60s with previously untreated metastatic SCAC receives chemotherapy and attains a complete response (29:21)
- Future directions for the treatment of SCAC (33:22)